Daiichi Sankyo claimed that a fixed-dose combination treatment, Tribenzor, simplifies dosing regimens and reduces pill burden. Research also shows that the use of fixed-dose antihypertensive combination treatments may improve patient compliance as compared to taking each medication separately.
Daiichi Sankyo’s Tribenzor is a combination of three prescribed antihypertensive medications, each working in a different way, to lower blood pressure.
Tribenzor is known to combine the complementary actions of olmesartan medoxomil (which blocks angiotensin II receptors), amlodipine (which inhibits the entrance of calcium into the blood vessel walls), and hydrochlorothiazide (a diuretic which reduces water volume in the blood). Together these three medications allow blood vessels to relax so that blood can flow more easily.
In the study, after eight weeks of treatment Tribenzor produced greater reductions in both systolic and diastolic blood pressures compared to each of the three dual combination therapies.
Joseph Izzo, chief of medicine of Erie County Medical Center, NY, said: “Tribenzor is a three-in-one pill that offers a simple and convenient therapy for patients, and may be just what some patients need to help bring their blood pressure to goal.”